Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: glycaemic control


Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

April 26th 2022

Once-weekly treatment with tirzepatide showed superior glycaemic control measured using CGM compared with insulin degludec in participants with type 2 diabetes on metformin, with or without a SGLT2 inhibitor. These new data provide additional evidence to the effect of tirzepatide and potential for achieving glycaemic targets without increase of hypoglycaemic risk compared with a basal insulin (The Lancet Diabetes & Endocrinology)

Categories: Medication, News
Tags: degludec, glycaemic control, SURPASS-3 CGM, tirzepatide, Type 2 Diabetes

Categories: Medication
Tags: degludec, glycaemic control, SURPASS-3 CGM, tirzepatide, Type 2 Diabetes

Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes

March 30th 2022

Analysis from the Dapagliflozin Effect on Cardiovascular Events trial (DECLARE-TIMI 58) on the association of baseline HbA1c with cardiovascular and kidney outcomes (Diabetes Care)

Categories: Cardiovascular, Nephropathy, News
Tags: glycaemic control, macrovascular, microvascular, Type 2 Diabetes

Categories: Cardiovascular, Nephropathy
Tags: glycaemic control, macrovascular, microvascular, Type 2 Diabetes

Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in T1D individuals, previously treated with MDI)

March 30th 2022

Children and adolescents with T1D on MDI therapy who initiated the AHCL system following a 10-days structured protocol achieved the internationally recommended goals of glycemic control with TIR > 70% and a HbA1c of < 7% (BMC Endocrine Disorders)

Categories: News, Paediatrics
Tags: closed-loop, glycaemic control, Type 1 Diabetes

Categories: Paediatrics
Tags: closed-loop, glycaemic control, Type 1 Diabetes

Achieving diabetes treatment targets in people with registered mental illness is similar or improved compared to those without: analyses of linked observational datasets

March 29th 2022

People with registered mental illness appear comparable or better able to achieve diabetes treatment targets than those without. Achieving HbA1c targets is influenced by social disadvantage (Diabetic Medicine)

Categories: News, Psychological
Tags: glycaemic control

Categories: Psychological
Tags: glycaemic control

Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation

March 14th 2022

This review evaluates current anti-hyperglycemic treatment in the context of AF, and discusses AF-related decision-making in comorbid DM (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: atrial fibrillation, glycaemic control

Categories: Cardiovascular
Tags: atrial fibrillation, glycaemic control

Glycemic Control and Clinical Outcomes in U.S. Patients With COVID-19: Data From the National COVID Cohort Collaborative (N3C) Database

February 28th 2022

In a large, multicenter cohort of patients in the U.S. with T2D and COVID-19 infection, risk of hospitalization increased with incrementally higher HbA1c levels. Risk of death and invasive ventilation also increased but plateaued at different levels of glycemic control (Diabetes Care)

Categories: News, Pathology
Tags: COVID-19, glycaemic control

Categories: Pathology
Tags: COVID-19, glycaemic control

Joint 30-year HbA1c and lipid trajectories and mortality in type 1 diabetes

February 18th 2022

These results suggest there is a subgroup with type 1 diabetes who, despite poor glycemic control, has a relatively good prognosis, perhaps related to good Non-HDLc (Diabetes Research and Clinical Practice)

Categories: News, Pathology
Tags: glycaemic control, HbA1c, lipid, Type 1 Diabetes

Categories: Pathology
Tags: glycaemic control, HbA1c, lipid, Type 1 Diabetes

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. The SURPASS-5 Randomized Clinical Trial

February 9th 2022

Among patients with type 2 diabetes and inadequate glycemic control despite treatment with insulin glargine, the addition of subcutaneous tirzepatide, compared with placebo, to titrated insulin glargine resulted in statistically significant improvements in glycemic control after 40 weeks (JAMA)

Categories: Medication, News
Tags: glargine, glycaemic control, insulin, tirzepatide, Type 2 Diabetes

Categories: Medication
Tags: glargine, glycaemic control, insulin, tirzepatide, Type 2 Diabetes

J-curve relationship between long term glycemic control and mortality in diabetic patients with acute myocardial infarction undergoing percutaneous coronary intervention

December 16th 2021

The less strict glycemic control in diabetic patients with AMI would be optimal for preventing mortality, especially in elderly patients (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: glycaemic control, MI

Categories: Cardiovascular
Tags: glycaemic control, MI

Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial

November 30th 2021

Closed-loop therapy is an effective treatment option for older adults with long-duration type 1 diabetes, and no safety issues were identified. These older adults had higher TIR accompanied by less time below range during closed-loop than during sensor-augmented pump therapy. Of particular clinical importance, closed loop reduced the time spent in hypoglycemic range overnight (Diabetes Care)

Categories: News, Treatment
Tags: closed-loop, elderly, glycaemic control, hypoglycemia, insulin, Type 1 Diabetes

Categories: Treatment
Tags: closed-loop, elderly, glycaemic control, hypoglycemia, insulin, Type 1 Diabetes

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence

November 8th 2021

This review intends to expose the probable molecular mechanisms and compile evidence of the synergistic or additive anti-inflammatory effects of SGLT2i and GLP-1RA and their potential impact on the management of patients with obesity and cardiorenal compromise (Journal of Diabetes Research)

Categories: Cardiovascular, Medication, News
Tags: GLP-1RA, glycaemic control, SGLT2 inhibitors

Categories: Cardiovascular, Medication
Tags: GLP-1RA, glycaemic control, SGLT2 inhibitors

Glycaemic control during the lockdown for COVID-19 in adults with type 1 diabetes: A meta-analysis of observational studies

September 23rd 2021

This meta-analysis shows that well-controlled people with type 1 diabetes on both MDI and CSII with continuous or flash glucose monitoring did not experience a deterioration in glucose control throughout the COVID-19 lockdown, showing a modest, though statistically significant improvement in many glucose control parameters (Diabetes Research and Clinical Practice)

Categories: Management, News
Tags: COVID-19, glycaemic control

Categories: Management
Tags: COVID-19, glycaemic control

Association of glycemic variability assessed by continuous glucose monitoring with subclinical diabetic polyneuropathy in type 2 diabetes

September 3rd 2021

The SDgluc is a significant independent contributor to subclinical diabetic polyneuropathy, in addition to conventional risk factors including diabetes duration and HbA1c (Journal of Diabetes Investigation)

Categories: Neuropathy, News
Tags: CGM, glycaemic control, glycemic variability, Type 2 Diabetes

Categories: Neuropathy
Tags: CGM, glycaemic control, glycemic variability, Type 2 Diabetes

Glycemic Variability and KIM-1–Induced Inflammation in the Diabetic Kidney

August 18th 2021

Recognition of DKD as an inflammatory disease linked by metabolic perturbations and immune responses is a central tenet that requires broader and deeper exploration (Diabetes)

Categories: Nephropathy, News
Tags: glycaemic control

Categories: Nephropathy
Tags: glycaemic control

Effects of intermittent very-low calorie diet on glycemic control and cardiovascular risk factors in obese patients with type 2 diabetes mellitus: A randomized controlled trial

August 4th 2021

Intermittent VLCD was highly effective in achieving optimal glycemic control. The effects of 2 days/week and 4 days/week of intermittent VLCD on diabetes remission were relatively similar (Journal of Diabetes Investigation)

Categories: Diet, News
Tags: glycaemic control, low-calorie, Type 2 Diabetes

Categories: Diet
Tags: glycaemic control, low-calorie, Type 2 Diabetes

Significant abnormal glycemic variability increased the risk for arrhythmias in elderly type 2 diabetic patients

April 29th 2021

The study demonstrated the elderly patients had greater glycemic variability and were more prone to arrhythmias. Therefore, active control of blood glucose fluctuation in elderly patients will help to reduce the risk of severe arrhythmia (BMC Endocrine Disorders)

Categories: Cardiovascular, News
Tags: arrhythmias, glycaemic control, Type 2 Diabetes

Categories: Cardiovascular
Tags: arrhythmias, glycaemic control, Type 2 Diabetes

Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone

April 7th 2021

Glycemia is strongly associated with β-cell dysfunction in adults with early T2DM treated with metformin alone. Efforts to improve glycemia should focus on interventions aimed at improving β-cell function (Journal of Diabetes and Its Complications)

Categories: News, Pathology
Tags: glycaemic control, metformin, Type 2 Diabetes, β-cell

Categories: Pathology
Tags: glycaemic control, metformin, Type 2 Diabetes, β-cell

The comparative effects of intensive glucose lowering in diabetes patients aged below or above 65 years: results from the ADVANCE trial

February 5th 2021

Our results suggest that an intensive glycaemic control strategy to reduce HbA1c to 6.5% provided broadly similar benefits and harms and may be recommended for older, as well as younger, patients (Diabetes, Obesity and Metabolism)

Categories: News, Treatment
Tags: glycaemic control

Categories: Treatment
Tags: glycaemic control

Acute glycaemic management before, during and after exercise for cardiac rehabilitation participants with diabetes mellitus

February 4th 2021

A joint statement of the British and Canadian Associations of Cardiovascular Prevention and Rehabilitation, the International Council for Cardiovascular Prevention and Rehabilitation and the British Association of Sport and Exercise Sciences (British Journal of Sports Medicine)

Categories: Cardiovascular, News
Tags: glycaemic control, rehabilitation

Categories: Cardiovascular
Tags: glycaemic control, rehabilitation

Glycemic control before admission is an important determinant of prognosis in patients with coronavirus disease 2019

November 25th 2020

HbA1c was an independent risk factor for poor outcomes in coronavirus disease 2019 patients. Severe pulmonary infection and consequent acute respiratory distress syndrome might be the primary causes of death in insufficient glycemic control patients (Journal of Diabetes Investigation)

Categories: News, Pathology
Tags: COVID-19, glycaemic control, HbA1c

Categories: Pathology
Tags: COVID-19, glycaemic control, HbA1c
  • 1
  • 2
  • 3
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Boehringer IngelheimAstraZenecaNovo NordiskNapp Diabetes

Silver Sponsors

About Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors elderly Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership